Current Headlines

  1. Thermo Fisher’s Oral Solid Dose Quick To Clinic™ – Milton Park, UK, And Horsham Sites Combine To Speed Products Into Phase I Clinical Trials
    5/21/2019

    When developing new pharmaceutical products, it is very important to get to the Phase I clinical trial in a fast, efficient and cost-effective way.

  2. Thermo Fisher’s Florence Site On Track For Commercial Spray Drying Services
    5/21/2019

    Formulation challenges for enhancing the bioavailability of poorly soluble API’s can be solved by spray drying.

  3. Thermo Fisher Scientific To Acquire Manufacturing Site In Cork, Ireland, From GSK
    5/16/2019

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs).

  4. Altasciences And WuXi AppTec Enter Into Collaboration For WIND Projects
    5/16/2019

    Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, announced today that they have entered into an agreement to support WuXi AppTec’s Investigational New Drug (WIND) platform. WIND combines world-class CRO services with cross-functional program management and global regulatory expertise to support IND applications. WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing

  5. Exelixis And Iconic Therapeutics Enter Into Exclusive Option And License Agreement For Novel Antibody-Drug Conjugate Program
    5/16/2019

    Exelixis, Inc. recently announced that it has entered into an exclusive option and license agreement with Iconic Therapeutics, Inc. (Iconic), a private biopharmaceutical company focused on cancer and retinal disease, to advance an innovative next-generation antibody-drug conjugate (ADC) program for cancer

  6. Wellspring Biosciences Announces Clearance Of IND Application To Initiate Phase 1 Trial Of KRAS G12C Mutant Inhibitor ARS-3248
    5/16/2019

    Wellspring Biosciences, Inc., a wholly owned subsidiary of Araxes Pharma, LLC, announced today that the U.S. Food and Drug Administration has cleared an investigational new drug (IND) application for ARS-3248, a small molecule KRAS G12C inhibitor

  7. Cue Biopharma Announces FDA Acceptance Of IND For Lead Immuno-Oncology Candidate, CUE-101, In Treatment Of HPV-Driven Cancers
    5/16/2019

    Cue Biopharma, Inc., (NASDAQ: CUE), an innovative clinical stage immunotherapy company, developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for its lead immuno-oncology candidate, CUE-101, an Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologic, as a potential treatment for HPV-associated cancers

  8. DEINOVE Is Now Ready To Start Phase II Clinical Trial For Its Antibiotic Compound DNV3837
    5/16/2019

    DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announced that all the conditions are in place for the upcoming start of the Phase II trial testing the antibiotic candidate DNV3837 for the treatment of Clostridioides difficile infections.

  9. Vertex And Kymera Therapeutics Establish Strategic Collaboration To Discover And Develop Targeted Protein Degradation Medicines For Serious Diseases
    5/15/2019

    Vertex Pharmaceuticals Incorporated and Kymera Therapeutics recently announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets

  10. Ginkgo Bioworks Acquires Warp Drive Bio's Genome Mining Platform For Discovery And Development Of Novel Classes Of Antibiotics
    5/15/2019

    Ginkgo Bioworks, the organism company, today announced it acquired the genome mining platform from Warp Drive Bio, a subsidiary of REVOLUTION Medicines, Inc. With the acquisition, Ginkgo will integrate Warp Drive Bio's genome mining team, technology, and database into its already vast codebase and premier platform for biological engineering